Breathe-Easy: Hayfever Care for Patients With Seasonal Allergic Rhinitis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

63 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-04-24

Study Completion Date

2024-06-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This waitlist-controlled trial aims to evaluate the therapeutic effectiveness of Hayfever Care by assessing disease-specific symptoms over a 4-week period. Additionally, the study examines the tolerability and safety of the solution.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Exploration Of Key Targets And Biomarkers Involved In An Allergic Response In Subjects With Allergic Rhinitis (Hay Fever)

NCT00348361

Allergic Rhinitis

COMPLETED PHASE1

Study on the Effect and Mechanism of Aescine Sodium in the Treatment of Allergic Rhinitis

NCT06709079

Allergic Rhinitis

NOT_YET_RECRUITING NA

Efficacy and Safety of Nasal Filters on Seasonal Allergic Rhinitis (Hay Fever)

NCT01699165

Rhinitis, Allergic, Seasonal

COMPLETED NA

Intratonsillar Immunotherapy for Allergic Rhinitis

NCT06523478

Allergic Rhinitis

RECRUITING NA

Study of a Topical Nasal Spray to Ease the Symptoms of Hayfever

NCT01500629

Rhinitis, Allergic, Seasonal

COMPLETED EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hayfever Allergy Pollen Allergic Rhinitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hayfever Care

Hayfever Care, a powdered natural food supplement.

Group Type EXPERIMENTAL

Hayfever Care

Intervention Type DIETARY_SUPPLEMENT

Powdered natural food supplement provided as a decoction, to be taken twice daily.

Personalized Diet and Nutrition Guidance along with Lifestyle Advice

Wait-list Care

No supplement was given during the trial period

Group Type OTHER

Wait-list Control

Intervention Type OTHER

Personalized Diet and Lifestyle Advice

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hayfever Care

Powdered natural food supplement provided as a decoction, to be taken twice daily.

Personalized Diet and Nutrition Guidance along with Lifestyle Advice

Intervention Type DIETARY_SUPPLEMENT

Wait-list Control

Personalized Diet and Lifestyle Advice

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Mettle's Hayfever Care

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Mild to moderate symptoms during the hayfever season
* Generally healthy individuals without chronic illnesses
* Willingness to comply with study requirements, including completing symptom diaries.

Exclusion Criteria

* History of anaphylaxis or severe hayfever symptoms requiring emergency treatment.
* Pregnant or breastfeeding
* History of substance abuse or excessive alcohol consumption.
* Use of systemic corticosteroids, immunotherapy

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No